Blind Weld and NIH (National Institutes of Health)

Or diastolic pressure> 110 mmHg. or changes in eye bottom - retinopathy associated with blood pressure), severe liver and kidney increased susceptibility to bleeding in patients with gastrointestinal disorders (eg peptic ulcer of the stomach or duodenum, credit availability of the gastrointestinal tract, ulcerative colitis with bleeding), increased susceptibility hemorahiy to patients with diseases of the genitourinary system (eg, urolithiasis, pyelonephritis and urinary system tumors), increased susceptibility to bleeding in patients with lung diseases that tend to formation Transitional Cell Carcinoma cavities (eg, open form of tuberculosis), bronchiectasis (with a penchant for hemoptysis ) rozsharovuyucha aortic aneurysm, endocarditis, G pancreatitis, severe bacterial sepsis, septic thrombosis, the first 4 weeks after childbirth, abortion or the threat of abortion, increased tendency to bleed with carcinoma, for not less than 4 weeks after translyumbalnoyi aortohrafiyi; for at least 8 days after credit availability lyumbalnoyi puncture; relative contraindications - diabetic retinopathy, vitreous hemorrhage in the body, the recent resuscitation, damage (congenital and acquired heart disease in the stage of decompensation) mitral valve with atrial fibrillation, thrombocytopenia, an abnormally elongated tromboplastynovyy time, partial tromboplastynovyy time and bleeding time, pregnancy (especially the first 18 weeks), damage the arteries that can not be peretysnuty. Method of production of drugs: Mr infusion, 0.75 mg / ml to 100 ml vial.; Mr injection, 2 mg / ml to 10 ml vial. cent. Side effects of drugs and complications in the use of drugs: microhematuria, bleeding from damaged vessels, hematoma, bleeding after needle or other invasive manipulation, g / injection, injury or fresh wounds, in rare cases - life-threatening bleeding (eg intracranial, Retroperitoneal, gastrointestinal, vnutrishnopechinkovi) transient rise in transaminase Tridal Volume and falling levels of hematocrit without any bleeding, manifested clinically, embolus formation, fever, AR (erythema, skin rash, Dyspnoe, arterial hypotension). Method of production of drugs: powder credit availability Mr credit availability and infusion of 10 000 IU, 250 000 IU, 000 IU, 500, 750 000 IU, 1000 000 IU in vial. Contraindications to the use of drugs: moved in the previous 10 days of surgery, trauma, biopsy, puncture nespadayuchoyi vessels (subclavian or credit availability vein), cardiac tamponade, endotracheal intubation, arterial lesions of the brain that can occur in severe hypertension, hypertensive or diabetic retinopathy, recently (up to 2 months) stroke or other cerebrovascular disease, aneurysms, bleeding or high risk of bleeding (hemorrhagic diathesis, thrombocytopenia, severe renal and / or liver failure, erosive-ulcerative lesions in the gastrointestinal tract prior 6 months - peptic ulcer, ulcerative colitis, diverticulitis, menstrual bleeding, during pregnancy - especially the first 18 weeks after delivery status, the active form of tuberculosis, tumors, pancreatitis g; risk of cardiac embolism, such as during atrial fibrillation Bundle Branch Block a background lesion of mitral valve bacterial endocarditis and, recently streptokinase treatment (from 5 days to 6 months. Indications for use drugs: G MI (within the first 12 h); deep vein thrombosis; G massive pulmonary embolism, arterial embolism hour occlusion or platelet; Creatine Phosphokinase hemodializnoho shunt. Method of production of drugs: lyophilized powder for preparation of district for injection 750 000 IU, by 1.5 million IU, 1.5 million IU in vial.